In the work report of the two sessions in 2018, the keyword of artificial intelligence was mentioned many times. This year's government work report emphasizes “strengthening the application and development of a new generation of artificial intelligenceâ€. In the ever-increasing wave of artificial intelligence, application landing has become the trend of the times. In the field of artificial intelligence, the topic of “AI+ Medical †is particularly worthy of attention. Medical has a wide range of branches, involving many industries, and it has both empirical and technical attributes. The industry believes that the combination of artificial intelligence and medical care can, on the one hand, achieve greater technology coverage based on the advantages of big data, and on the other hand, help to improve the fineness and professionalism of the entire industry level. Especially after the “Healthy China†slogan was raised and raised to the national strategic level, the capital market also began to shift its focus to the medical field. How much is this industry optimistic? Recently, four AI medical startups announced financing information on the same day, with a total amount of several hundred million yuan. Among them, in the short period of one year, Shenrui Medical has won a total of three rounds of financing of 300 million yuan, which is also rare in the industry, and also reflects the industry's ability to absorb gold. 4 AI medical startups announced financing on the same day The first to detonate this day is Shenrui Medical. On the morning of April 2, Shenrui Medical announced the completion of the 150 million yuan B round of financing, led by Junlian Capital, Lenovo Star and investment, A round and A round + investment side Danhua Capital, Kunzhong Capital, Tongdu Capital, Dow Investment and Hongdao Capital continued to follow suit. After this round of financing, Shenrui Medical will continue to expand its product line, build a multi-level marketing system, expand cooperation with medical institutions, and achieve commercialization. At the same time, the company will continue to increase investment in scientific research and expand research and development projects in North America. Founded in early 2017, Shenrui Medical is a developer of artificial intelligence medical applications, covering medical image recognition, early screening of various malignant diseases, and accurate diagnostic solutions. Previously, in September 2017, Shenrui Medical received a round of financing of 35 million yuan; in November 2017, it was awarded A+ round of financing, led by Danhua Capital, Daoyi Investment, Tongdu Capital, Hongdao Capital and Investment. So far, within one year of establishment, the accumulated financing amount of Shenzhen Rui Medical has reached 300 million yuan. Just over ten minutes later, the financing news of another AI medical company Airdoc was also announced. Airdoc announced that it has completed the multi-billion-yuan B-round financing of Fosun's leading investment and Sogou investment, and the three parties will jointly explore the path of medical artificial intelligence industry. It also announced the establishment of a smart prevention and control system for chronic diseases that is integrated online and offline with Fosun and Sogou. Airdoc pointed out that after the completion of this round of financing, Airdoc will replicate the successfully applied application scenarios and business models, and cooperate with hospitals, insurance companies, pharmaceutical companies, and health management companies to accelerate medical AI based on existing product lines. Large-scale application of technology. An hour later, AI Medical Imaging Company saw that Technology announced that it had completed a 60-yuan A round of financing recently. This round of financing was led by Shenzhen Venture Capital, and Shengshi Ark and Shanshan Investment and Investment. Vision Technology is an innovative company that emphasizes the accumulation of original technology and applies artificial intelligence to medical imaging. The core is to develop high-quality medical impact analysis software and large-scale images based on artificial intelligence deep learning and computer medical image analysis technology. The processing platform intelligently identifies and analyzes medical image big data, and provides advice on auxiliary medical treatment programs quickly and accurately, thereby improving the accuracy and efficiency of clinical diagnosis and treatment. Previously, Vision Technology was awarded the Hong Kong Science and Technology Innovation Agency's multi-million dollar subsidy and Lenovo Venture Capital's nearly 20 million yuan Pre-A round of financing. At noon, the Kangfuzi team announced the completion of tens of millions of A+ rounds of financing, the investors are the morning mountain fund of broadband capital. It is reported that the financing will be used for the research and development of the team in the field of medical artificial intelligence. Kangfuzi is a company specializing in the field of medical and health. It was established in April 2015. Based on the automatic extraction technology of unstructured information, it quickly extracts information from medical books, medical papers, electronic medical records and medical information to build a knowledge map. Auxiliary doctors make clinical decisions. In January 2016, Kang Fuzi received a seed round financing of several million yuan in hunting capital; in October 2016, he received tens of millions of angel round financing from Morningside Capital; in July 2017, he obtained the A round of volcanic stone capital. Financing. So far, on April 2, a total of four AI medical startups announced financing, the total amount of up to 300 million yuan, the capital heat can be seen. "AI+Medical" has a bright future “AI+Medical†usually refers to the application of new technologies and means such as artificial intelligence, big data, Internet of Things, and cloud computing to medical service subjects, medical institutions, and medical service objects. Insiders pointed out that "AI+Medical" can be divided into six types of landing scenes. The first category is the prediction of epidemics; the second category is for face recognition and verification in the course of diagnosis and treatment; the third category is to use medical data to assist diagnosis and improve the accuracy of diagnosis and treatment; the fourth category is precision surgery. The fifth category is for medical research and development; the sixth category is for “AI+ Health Managementâ€. On July 8, 2017, the State Council issued the "New Generation Artificial Intelligence Development Plan", proposing to develop smart medical care, promote new methods and new methods of applying artificial intelligence treatment, and establish a fast and accurate intelligent medical system. Some investors believe that the development of “AI+Medical†has already supported the policy level. With the intervention of the entire capital market, the application of artificial intelligence in the medical field is bound to rise to the next level. Li Jiaqing, managing director of Junlian Capital, which has invested in a number of “AI+Medical†startups, pointed out that medical imaging is the most important clinical diagnostic and differential diagnostic tool in modern medicine. The continuous enrichment of imaging technology has transformed medical imaging from auxiliary inspection tools. At the stage of the doctor's diagnosis, the largest information portal, nearly 70% of clinical diagnosis requires medical imaging. The value of medical imaging AI lies in the efficient cooperation between clinicians and imaging doctors, reducing the rate of misdiagnosis. When data becomes a new production factor, artificial intelligence technology has created a new supply of medical services. However, artificial intelligence has only a single breakthrough in medical imaging, and it is far from enough to understand that the medical industry is critical to the application of products. Qiao Wei, CEO of Shenrui Medical, believes that the application of artificial intelligence in the medical field is still in a relatively shallow stage. Shenrui Medical believes that the application of artificial intelligence in the medical field has great potential. In the future, artificial intelligence will be more in all fields of medical treatment. Perfect performance, while effectively integrating and improving the existing level of diagnosis and treatment. According to Chen Hao, founder of Vision Technology, the medical industry faces difficulties such as shortage of high-quality resources for doctors and rapid increase in image data. The massive data learning and accurate analysis of artificial intelligence brings new opportunities for the development of the medical industry. The arrival of AI will not replace the doctor, but will play the role of assistant doctor diagnosis, as a fast and accurate analysis tool to achieve the purpose of screening and treating diseases. Xu Hang, managing partner of SAIF Health Industry, bluntly said that he is very optimistic about the future application of artificial intelligence and big data in the field of medical and health. "Artificial intelligence is very promising in this field. There are many things that can be learned through machine learning. As a country with a large population, China must have a way to provide services efficiently, but at present China's medical services are seriously inadequate in terms of capital investment. Artificial intelligence can improve the overall doctor's diagnosis level in many ways, for example, through diagnostic assistants. However, I can't predict how much artificial intelligence will promote the health care industry in the next five years. It is interdisciplinary. It depends on its own level of development." (Securities Times) Organic Buckwheat Grass Powder Organic Buckwheat Grass Powder,Buckwheat Leaf Powder,Young Buckwheat Grass Powder,Buckwheat Young Leaf Powder Hengshui Shanzhi Health Drink Co., Ltd , https://www.grasspowder-sz.com